Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has earned an average rating of “Buy” from the seven analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $7.35.
CPRX has been the topic of several recent research reports. BidaskClub raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, February 25th. ValuEngine cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 1st. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $10.00 price target on shares of Catalyst Pharmaceuticals in a research note on Tuesday, March 19th. Zacks Investment Research raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research note on Tuesday, May 21st. Finally, HC Wainwright set a $9.00 target price on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, May 14th.
CPRX stock traded down $0.05 during midday trading on Monday, hitting $3.80. The stock had a trading volume of 1,279,828 shares, compared to its average volume of 2,089,157. The stock has a market cap of $390.83 million, a price-to-earnings ratio of -11.52 and a beta of 2.71. The stock’s 50-day moving average price is $3.89. Catalyst Pharmaceuticals has a 52-week low of $1.85 and a 52-week high of $6.16. The company has a current ratio of 6.08, a quick ratio of 6.07 and a debt-to-equity ratio of 0.02.
In related news, CEO Patrick J. Mcenany bought 25,000 shares of the business’s stock in a transaction dated Tuesday, June 11th. The shares were purchased at an average cost of $3.23 per share, with a total value of $80,750.00. Following the completion of the purchase, the chief executive officer now owns 4,762,693 shares in the company, valued at approximately $15,383,498.39. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 10.70% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CPRX. Bank of New York Mellon Corp grew its position in Catalyst Pharmaceuticals by 12.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 308,580 shares of the biopharmaceutical company’s stock worth $1,166,000 after purchasing an additional 33,767 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Catalyst Pharmaceuticals by 9.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 989,080 shares of the biopharmaceutical company’s stock worth $3,739,000 after acquiring an additional 86,692 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 4.3% during the 3rd quarter. Vanguard Group Inc. now owns 4,458,151 shares of the biopharmaceutical company’s stock worth $16,852,000 after acquiring an additional 185,017 shares during the period. Rhumbline Advisers lifted its holdings in shares of Catalyst Pharmaceuticals by 49.9% during the 4th quarter. Rhumbline Advisers now owns 126,699 shares of the biopharmaceutical company’s stock worth $243,000 after acquiring an additional 42,199 shares during the period. Finally, Alps Advisors Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 30.8% during the 4th quarter. Alps Advisors Inc. now owns 237,439 shares of the biopharmaceutical company’s stock worth $456,000 after acquiring an additional 55,884 shares during the period. 59.79% of the stock is currently owned by hedge funds and other institutional investors.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
Featured Article: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.